Clinical Trial Update: Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs） [Phase 1]

View source ↗

Summary

Phase 1 trial update showing that HN2301 is being studied for autoimmune diseases with ongoing recruitment, including systemic lupus erythematosus, systemic scl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• HN2301 (HN2301)

Snippet

Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd | Conditions: Systemic Lupus Erythematosus, Scleroderma | Phase 1 | Status: RECRUITING